Member Info for RayPointer

WTP
Scancell's home page may hold a clue or two on this.

https://www.scancell.co.uk/

It shows one of the Glycans mAbs i.e. SC129 quite well into pre-clinical work.
I don't know how often Scancell update this page but I don't think it has been updated for at least a couple of months.
Hard to say but maybe Lindy is close having the pre-clinical data and is considering a deal on this particular mAb.
Speculation, I know.

Perhaps it's just more likely that it's a recognition that multiple things are happening at various stages and people are thinking its better to be in than out.
Lindy did say to expect multiple inflection points :-)
We've heard it before but maybe this time it is for real

Perhaps the market has woken up to the fact that Scancell have 3 products in the clinic and no less than 6 products pre-clinical.
Add to that the possibility of Glycans deals, and maybe new and existing investors are thinking it is worth a punt.

Forget the trial results, its the golden cross everybody is excited about, especially if it occurs on a full moon.

Possibly it is more important to look what the new starters are expected to do

The first vacancy seems to be all about analysing and compiling patient data from the 3 trials. This is possibly a good sign that the trials are going as expected.

"Key duties and responsibilities:

Perform immunology-based assays such as T cell culture, ELISpot assay, flow cytometry, cell killing, multiplex assays using the Mesoscale discovery platform.
Perform T cell-based assays, including isolation and culture of T cells from tumours or peripheral blood samples.
Perform immunological assays on clinical trial samples in accordance with the clinical trial study protocols.
Take a lead role in the management of patient sample analysis, planning and coordinating assays/resources.
Conduct comprehensive data analysis, data presentation, report writing and communication of results.
Be responsible for line management of a technician."

The second vacancy is about the testing of NEW Glycans mAbs.

"Key duties and responsibilities:

Design and execute experiments to generate new GlyMab® mAbs using standard hybridoma as well B cell repertoire mining technologies
Validation of mAb target binding (ELISA and Biacore) and target distribution (cell-based and immunohistochemical analyses)
Analyses of in vitro and in vivo mAb-mediated tumour killing through a range of mAb formats
Data analysis as well as recording and presenting results
Frequent review of relevant literature to contribute to project progression"

So let's not get hung up on numbers of employees and focus more on what the new employees are expected to do.
Both roles are very interesting and the second shows that the science is still expanding. Also remember that, if Scancell's policy remains the same, the Glycans mAbs are all aimed at pre-clinical deals (apart from the TCB antibody aspect for which Scancell intend to move into the clinic)

great minds think alike!

Drac
They have access to state of the art labs in the Nottingham Uni biodiscovery centre and recently they also set up an additional lab in the Oxford Science Park.
My post was having a bit of fun with hasiba who had a mad panic attack one weekend and wanted proof that Scancell had a lab.

"Fundamentals haven’t changed"
Scancell still haven't got a lab

COYC

If Lindy were to publish the results of the Covidity at year end or thereabouts, it may be a great time to do this especially if there are indications that it will work against not just omicron but any future variants.
The immumogenicity relating to the N protein may be key to this.

One of the factors is how long the current vaccines last.

https://www.healthline.com/health/how-long-does-covid-vaccine-protect-you

and how effective they are against omicron

https://www.healthline.com/health-news/by-the-numbers-covid-19-vaccines-and-omicron

Lindy did hint at the last AGM that a deal for Immunobody would be possible.
This was in answer to a question on Covidity. She also said that Scancell intends to publish the trial results before seeking a deal.

"Firstly, glycosylation is discussed. This is the PTM responsible for the creation of glycans which of course are the targets for Scancell's GlyMab platform. Very much in line with Lindy Durrant's previous comments, targeting glycans seems to have been a hard nut to crack for developers. "

As highlighted by Bermuda, I wonder if Genentech are one of Scancell's 4 collaborators on the Glycans mAbs.

Excellent Bermuda.
It's nice to know that Genetech still appear to be following Lindy's work.
I don't know if any of you remember this presentation by Scancell back in 2018

https://www.youtube.com/watch?v=zogJ2CCmOxY&t=8s

At about 12 minutes 50 into the presentation Lindy talks about the grand challenge. She explains the collaboration of Biontech and Genentech on personalised neoantigens and why they were both interested in Moditope.

So who is setting the odds that Scancell will succeed and what are those odds?

Evening Matt
IMO it's a very risk averse market with everything that is going on at the moment.
Logic doesn't come into it with a lot of investors. Fear has taken over.
All that can change in the twinkling of an eye, with Scancell better placed than ever before to start realising that potential :-)

https://en.wikipedia.org/wiki/Tetramer_assay#:~:text=A%20tetramer%20assay%20%28also%20known%20as%20a%20tetramer,a%20given%20antigen%20within%20a%20blood%20sample.%20

I wonder if Scancell have access to the required equipment at the Biodiscovery centre at Nottingham, whereas they may not have the equipment at their Oxford lab. That may explain why the latest recruit is based in Nottingham rather than Oxford.

This job seems different from many of the recently advertised job which have been based at the lab in Oxford.
Also it requires a PHD.

Yes, you are right. I had forgotten that all patients in the original 40 planned were to receive both SCOV1 and SCOV2.
Thanks for the correction.
Let's hope you are correct and we can expect an update very soon.
ATB

Hi Johnny

You may be correct but, on the other hand, the original protocol was for SCOV1 and SCOV2 with 2 different injection devices.
So originally there were 4 cohort of 10 each. Whether that was reduced to 2 cohorts of 11 each is not clear.
It may be that, by now, they have enough evidence overall to know
a) Whether SCOV1 or SCOV2 is more effective
and
b) Which of the 2 injection devices is better.
So, at this point they may just be increasing the numbers to make the overall results more statistically significant for certain of the populations.

It does sound like a flexible approach from the following statement:

"However, should the epidemiology be such that certain populations cannot be enrolled, the Safety Review Committee may determine that enrolment for that population be considered complete."

The amendment was made on June 2, so almost 3 months on perhaps we are nearing the end of recruitment.

https://www.withpower.com/trial/phase-1-covid-19-8-2021-ac2e4

As posted by JohnnyB several days ago.
Is it significant that this advert is for Scov2 only?
Does it mean that recruitment for the first part of the trial (Scov1 and Scov2) is now complete?
Alternatively, perhaps it is now nigh on impossible to recruit people who have neither had the infection nor have not been vaccinated.
Either way, it looks that maybe the trial organisers are now concentrating on the booster half of the trial.